Abstract: Objective To investigate the value of adefovir dipivoxil combined with lamivudine treatment after lamivudine resistance in chronic hepatitis B patients with HBeAg positive. Methods Patients were divided into two groups. Group A were treated with  lamivudine associated with adefovir dipivoxil after lamivudine resistance. Group B were treated with adefovir dipivoxil instead of lamivudine. HBV DNA was detected by real-time PCR, and HBV markers were detected by ELISA. ALT and AST were also detected. Results After 48 weeks treatment, the normalization rate of ALT in group A was 88.6%, the rate of HBV DNA undetectable was 80.5%, the rate of HBeAg undetectable was 35.8%, and anti-HBe serum conversion rate was 16.7%. Meanwhile,  the normalization rate of ALT in group B was 77.8%, the rate of HBV DNA undetectable was 63.9%, the rate of HBeAg undetectable was 16.7%, and anti-HBe serum conversion rate was 13.0%. All indexes in group A were bviously higher than those in group B, with statistical difference. Conclusions Effect of lamivudine ssociated with adefovir dipivoxil in treatment of chronic hepatitis B patients after lamivudine resistance is better than swiching to adefovir dipivoxil.